RxDoctor Payments Data

Isaac Gorbaty, MD

Nephrology · Tarzana, CANPI 1477562718

Payments from drug & device makers

$413in general payments, 2019–2025

Across 17 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$63
  • Pfizer$42
  • Otsuka America Pharmaceutical, Inc.$40
  • Madrigal Pharmaceuticals$37
  • Travere Therapeutics, Inc.$33
  • AstraZeneca$29
  • plus $169 from 8 others

What the payments were for

  • Food & beverage$37591%
  • Education$389%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$413 in reported general payments places this provider in the 30th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$152,400
Medicare patients
235
Services billed
7,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$63,763
EliquisApixaban58$56,243
MounjaroTirzepatide38$48,915
JardianceEmpagliflozin36$41,227
JanuviaSitagliptin Phosphate17$23,883
XareltoRivaroxaban20$20,470
RestasisCyclosporine19$16,505
Repatha SureclickEvolocumab27$15,671
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate12$15,167
RexultiBrexpiprazole11$14,269
LinzessLinaclotide16$10,338
GemtesaVibegron15$7,249
DilantinPhenytoin Sodium Extended13$6,295
Breo ElliptaFluticasone/Vilanterol11$5,992
MyrbetriqMirabegron12$5,941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$42$62,53871 claims
AbbVieRestasis, Linzess, Namzaric, Synthroid$63$34,47277 claims
MerckJanuvia$17$23,88317 claims
Otsuka America Pharmaceutical, Inc.Rexulti$40$14,26911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,341 nephrology providers in California.

Other nephrology in Tarzana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →